Afficher la notice abrégée

Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studies

dc.rights.licenseopenen_US
dc.contributor.authorHEIER, Jeffrey S
dc.contributor.authorLAD, Eleonora M
dc.contributor.authorHOLZ, Frank G
dc.contributor.authorROSENELD, Philip J
dc.contributor.authorGUYMER, Robyn H
dc.contributor.authorBOYER, David
dc.contributor.authorGROSSI, Federico
dc.contributor.authorBAUMAL, Caroline R
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorKOROBELNIK, Jean-Francois
dc.contributor.authorSLAKTER, Jason S
dc.contributor.authorWAHEED, Nadia K
dc.contributor.authorMETLAPALLY, Ravi
dc.contributor.authorPEARCE, Ian
dc.contributor.authorSTEINLE, Nathan
dc.contributor.authorFRANCONE, Anibal A
dc.contributor.authorHU, Allen
dc.contributor.authorLALLY, David R
dc.contributor.authorDESCHATELETS, Pascal
dc.contributor.authorFRANCOIS, Cedric
dc.contributor.authorBLISS, Caleb
dc.contributor.authorSTAURENGHI, Giovanni
dc.contributor.authorMONES, Jordi
dc.contributor.authorSINGH, Rishi P
dc.contributor.authorRIBEIRO, Ramiro
dc.contributor.authorWYKOFF, Charles C
dc.date.accessioned2025-04-11T06:45:21Z
dc.date.available2025-04-11T06:45:21Z
dc.date.issued2025-01-17
dc.identifier.issn1750-7448en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206113
dc.description.abstractEnWhat is this summary about?This is a summary of the results of 2 clinical studies , called OAKS and DERBY, that tested a medicine called pegcetacoplan. Pegcetacoplan is the first United States Food and Drug Administration (US FDA) approved treatment for geographic atrophy, commonly referred to as GA, a common eye disease in older people. Geographic atrophy is a form of late age-related macular degeneration, or AMD, that usually starts after age 50. The US FDA approved pegcetacoplan based on the results from these 2 clinical studies. Pegcetacoplan is covered by Medicare and most insurance companies in the United States.What are the key takeaways?The results of the OAKS and DERBY clinical studies show that treatment with pegcetacoplan led to slower growth of GA lesions in the retina. The retina is the light-sensitive tissue at the back of the eye. In other words, it slowed the growth of the areas where cells were dying. When compared to a sham procedure, pegcetacoplan injection slowed the growth of lesions by 19% to 22% (when given every 4 weeks) and 16% to 18% (when given every 8 weeks) in OAKS and DERBY, respectively.After 2 years of treatment, there were no differences in the average vision function between participants treated with pegcetacoplan and participants who received a sham procedure.The most common eye-related health issues reported were like those reported with all types of intravitreal injections and most were temporary.What were the main conclusions reported by the researchers?Based on the results of these 2 large clinical studies, pegcetacoplan slows GA disease progression with an incidence of eye-related health issues similar to other drugs given by intravitreal injection.[Box: see text]. eng
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.title.enPegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studies
dc.title.alternativeImmunotherapyen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1080/1750743x.2025.2449760en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39819346en_US
bordeaux.journalImmunotherapyen_US
bordeaux.page1-15en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-05030189
hal.version1
hal.date.transferred2025-04-11T06:45:26Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Immunotherapy&rft.date=2025-01-17&rft.spage=1-15&rft.epage=1-15&rft.eissn=1750-7448&rft.issn=1750-7448&rft.au=HEIER,%20Jeffrey%20S&LAD,%20Eleonora%20M&HOLZ,%20Frank%20G&ROSENELD,%20Philip%20J&GUYMER,%20Robyn%20H&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_ImmunoT_2025_Heier.pdf
Taille:
5.249Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
811octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée